vs

Side-by-side financial comparison of ARDELYX, INC. (ARDX) and DHT Holdings, Inc. (DHT). Click either name above to swap in a different company.

DHT Holdings, Inc. is the larger business by last-quarter revenue ($107.3M vs $94.5M, roughly 1.1× ARDELYX, INC.). DHT Holdings, Inc. runs the higher net margin — 41.7% vs -39.8%, a 81.5% gap on every dollar of revenue. On growth, ARDELYX, INC. posted the faster year-over-year revenue change (27.5% vs -24.5%).

Ardelyx, Inc. is a commercial-stage biopharmaceutical firm developing and commercializing innovative therapies for gastrointestinal, cardiorenal and metabolic diseases with high unmet medical needs. Its lead product is approved in the US for irritable bowel syndrome with constipation, and it holds a robust pipeline of early and late-stage drug candidates.

DHT Holdings, Inc. is an independent international crude oil tanker operator that owns and manages a fleet of very large crude carriers. It offers marine transportation services for crude oil across major global trade routes, serving clients including leading oil producers, refineries, and commodity trading enterprises worldwide.

ARDX vs DHT — Head-to-Head

Bigger by revenue
DHT
DHT
1.1× larger
DHT
$107.3M
$94.5M
ARDX
Growing faster (revenue YoY)
ARDX
ARDX
+51.9% gap
ARDX
27.5%
-24.5%
DHT
Higher net margin
DHT
DHT
81.5% more per $
DHT
41.7%
-39.8%
ARDX

Income Statement — Q1 FY2026 vs Q3 FY2025

Metric
ARDX
ARDX
DHT
DHT
Revenue
$94.5M
$107.3M
Net Profit
$-37.6M
$44.8M
Gross Margin
Operating Margin
44.2%
Net Margin
-39.8%
41.7%
Revenue YoY
27.5%
-24.5%
Net Profit YoY
27.3%
EPS (diluted)
$-0.15
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ARDX
ARDX
DHT
DHT
Q1 26
$94.5M
Q4 25
$125.2M
Q3 25
$110.3M
$107.3M
Q2 25
$97.7M
Q1 25
$74.1M
Q4 24
$116.1M
Q3 24
$98.2M
$142.1M
Q2 24
$73.2M
Net Profit
ARDX
ARDX
DHT
DHT
Q1 26
$-37.6M
Q4 25
$-407.0K
Q3 25
$-969.0K
$44.8M
Q2 25
$-19.1M
Q1 25
$-41.1M
Q4 24
$4.6M
Q3 24
$-809.0K
$35.2M
Q2 24
$-16.5M
Gross Margin
ARDX
ARDX
DHT
DHT
Q1 26
Q4 25
91.3%
Q3 25
96.4%
Q2 25
87.3%
Q1 25
83.4%
Q4 24
84.3%
Q3 24
84.0%
Q2 24
87.1%
Operating Margin
ARDX
ARDX
DHT
DHT
Q1 26
Q4 25
4.1%
Q3 25
4.2%
44.2%
Q2 25
-14.7%
Q1 25
-49.0%
Q4 24
7.0%
Q3 24
2.3%
29.7%
Q2 24
-18.6%
Net Margin
ARDX
ARDX
DHT
DHT
Q1 26
-39.8%
Q4 25
-0.3%
Q3 25
-0.9%
41.7%
Q2 25
-19.5%
Q1 25
-55.5%
Q4 24
4.0%
Q3 24
-0.8%
24.8%
Q2 24
-22.5%
EPS (diluted)
ARDX
ARDX
DHT
DHT
Q1 26
$-0.15
Q4 25
$-0.01
Q3 25
$0.00
$0.28
Q2 25
$-0.08
Q1 25
$-0.17
Q4 24
$0.01
Q3 24
$0.00
$0.22
Q2 24
$-0.07

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ARDX
ARDX
DHT
DHT
Cash + ST InvestmentsLiquidity on hand
$238.1M
$81.3M
Total DebtLower is stronger
$203.5M
Stockholders' EquityBook value
$148.6M
$1.1B
Total Assets
$504.5M
$1.4B
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ARDX
ARDX
DHT
DHT
Q1 26
$238.1M
Q4 25
$68.0M
Q3 25
$42.7M
$81.3M
Q2 25
$90.0M
Q1 25
$30.8M
Q4 24
$64.9M
Q3 24
$47.4M
$73.8M
Q2 24
$41.9M
Total Debt
ARDX
ARDX
DHT
DHT
Q1 26
$203.5M
Q4 25
$202.8M
Q3 25
$202.1M
Q2 25
$201.4M
Q1 25
$151.3M
Q4 24
$150.9M
Q3 24
$100.7M
Q2 24
$100.2M
Stockholders' Equity
ARDX
ARDX
DHT
DHT
Q1 26
$148.6M
Q4 25
$166.9M
Q3 25
$154.3M
$1.1B
Q2 25
$139.5M
Q1 25
$145.7M
Q4 24
$173.3M
Q3 24
$158.3M
$1.0B
Q2 24
$147.0M
Total Assets
ARDX
ARDX
DHT
DHT
Q1 26
$504.5M
Q4 25
$501.6M
Q3 25
$486.2M
$1.4B
Q2 25
$466.8M
Q1 25
$410.2M
Q4 24
$435.8M
Q3 24
$367.9M
$1.5B
Q2 24
$343.5M
Debt / Equity
ARDX
ARDX
DHT
DHT
Q1 26
1.37×
Q4 25
1.21×
Q3 25
1.31×
Q2 25
1.44×
Q1 25
1.04×
Q4 24
0.87×
Q3 24
0.64×
Q2 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ARDX
ARDX
DHT
DHT
Operating Cash FlowLast quarter
$60.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
1.36×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ARDX
ARDX
DHT
DHT
Q1 26
Q4 25
$21.0M
Q3 25
$365.0K
$60.9M
Q2 25
$-25.3M
Q1 25
$-38.5M
Q4 24
$9.8M
Q3 24
$501.0K
$80.1M
Q2 24
$-19.4M
Free Cash Flow
ARDX
ARDX
DHT
DHT
Q1 26
Q4 25
$20.6M
Q3 25
$209.0K
Q2 25
$-26.0M
Q1 25
$-38.8M
Q4 24
$9.2M
Q3 24
$364.0K
Q2 24
$-19.5M
FCF Margin
ARDX
ARDX
DHT
DHT
Q1 26
Q4 25
16.4%
Q3 25
0.2%
Q2 25
-26.6%
Q1 25
-52.3%
Q4 24
7.9%
Q3 24
0.4%
Q2 24
-26.7%
Capex Intensity
ARDX
ARDX
DHT
DHT
Q1 26
Q4 25
0.3%
Q3 25
0.1%
Q2 25
0.7%
Q1 25
0.4%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.2%
Cash Conversion
ARDX
ARDX
DHT
DHT
Q1 26
Q4 25
Q3 25
1.36×
Q2 25
Q1 25
Q4 24
2.11×
Q3 24
2.28×
Q2 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ARDX
ARDX

IBSRELA$70.1M74%
XPHOZAH$23.3M25%
Non-cash royalty revenue related to the sale of future royalties$695.0K1%
Product supply revenue$354.0K0%

DHT
DHT

Segment breakdown not available.

Related Comparisons